Xin-Hua Zhu

Dr. Xin-Hua Zhu

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
RQRyann Quinn
Ryann Quinn
RPRajvi Patel
Rajvi Patel
CSCristina Sison
Cristina Sison
ASAmandeep Singh
Amandeep Singh
XZXin-Hua Zhu
Xin-Hua Zhu
Purpose: The strategy of precision medicine has been widely adopted in the practice of oncology, although the efficacy remains unclear. This study assesses clinical outcomes in patients with an actionable alteration found during FoundationOne CDx™ (F1CDx) testing and who received a targeted therapy based on the results. Materials and Methods: This is a retrospective cohort study of patients with tumors that underwent F1CDx from September 2012 to July 2018. F1CDx provided actionable alterations for patients to select appropriate therapies. The primary objective was to estimate the objective response rate (ORR) at 3 months from the start of study treatment. The secondary objectives were to estimate progression-free survival (PFS) and overall survival (OS). Results: One thousand patients underwent F1CDx testing. Six hundred fifty-two patients were identified as having actionable mutations. Thirty-eight patients (18 males and 20 females) received targeted therapy and were included in the study. The most common alterations were PD-1/PDL-1, high-TMB, P13K, and HER2/ERBB2. Patients received various treatments including nivolumab, pembrolizumab, trastuzumab, and everolimus. Eight (23.5%) and six (17.7%) patients achieved partial response (PR) and stable disease (SD), respectively; 20 (58.8%) had progression of disease (PD). The disease control rate was 41.2% (95% CI: 24.7% to 59.3%). The median PFS was 2.7 months (95% CI: 2.3 to 5.4 months), and median OS was 9.9 months (95% CI: 4.5 to 33.7 months). Conclusion: Our results demonstrate promising data in precision medicine in real community oncology practice. It warrants further large and prospective studies in patients with actionable alterations.

1 January 2021 in Journal of Cancer
Verified
Journal Article
Open access
TFTakeo Fujii
Takeo Fujii
HRHasan Rehman
Hasan Rehman
SCSu Yun Chung
Su Yun Chung
JSJanice Shen
Janice Shen
JNJames Newman
James Newman
XZXin-Hua Zhu
Xin-Hua Zhu
Background: Survival outcome after developing brain metastasis is poor and there is an unmet need to identify factors that can promote brain metastasis. Granulocyte-colony stimulating factor (G-CSF) is given to support neutrophil recovery after myelosuppressive chemotherapy to some patients. However, there is emerging evidence that neutrophils can promote metastasis, including through the formation of neutrophil extracellular traps (NETs), scaffolds of chromatin with enzymes expelled from neutrophils to the extracellular space. In animal models, G-CSFs can induce NETs to promote liver and lung metastasis. The primary objective of this study was to test the association between G-CSF use and the later incidence of brain metastasis.

1 February 2019 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
NMNeal Murphy
Neal Murphy
JSJanice Shen
Janice Shen
ASAndrew Shih
Andrew Shih
ALAnthony Liew
Anthony Liew
HKHouman Khalili
Houman Khalili
XZXin-Hua Zhu
Xin-Hua Zhu

2 November 2022 in Oncotarget
Verified
Journal Article
Open access
PDF file
NMNeal Murphy
Neal Murphy
ASAndrew J. Shih
Andrew J. Shih
PSParas Shah
Paras Shah
OYOksana Yaskiv
Oksana Yaskiv
HKHouman Khalili
Houman Khalili
XZXin-Hua Zhu
Xin-Hua Zhu
Https://doi.org/10.18632/oncotarget.28302 Neal Murphy, Andrew J. Shih, Paras Shah, Oksana Yaskiv, Houman Khalili, Anthony Liew, Annette T. Lee, Xin-Hua Zhu

19 March 2026 in Cancers
Verified
Journal Article
Open access
PDF file
JHJing Huang
Jing Huang
XZXin-Hua Zhu
Xin-Hua Zhu
LTLloyd C Trotman
Lloyd C Trotman
CTChe-Kai Tsao
Che-Kai Tsao
Prostate cancer (PCa) is one of the most common malignancies in men, and growing evidence implicates the gut microbiome as a significant, modifiable contributor to disease evolution and management. Dysbiosis influences PCa biology through effects on inflammation, immune regulation, metabolism, and hormone signaling. Microbial imbalance can promote systemic inflammation and increase intestinal permeability, activating immune signaling pathways such as NF-κB–IL-6–STAT3. In parallel, microbiome-driven metabolic effects, including IGF-1 signaling and microbial androgen synthesis or recycling, may contribute to resistance to androgen deprivation therapy (ADT). Microbial metabolites, notably short-chain fatty acids (SCFAs) and trimethylamine N-oxide (TMAO), exert context-dependent effects on tumor growth, treatment resistance, and progression. Conversely, beneficial microbes have been associated with improved treatment sensitivity and immune regulation. Together, these insights support the gut microbiome as a potential biomarker and emerging therapeutic target in PCa. Modulation strategies, including diet, probiotics, antibiotics, and fecal microbiota transplantation (FMT), are being explored to improve treatment response and address resistance. As mechanistic evidence continues to grow, ongoing monitoring of the gut microbiome may help inform risk stratification and treatment optimization in prostate cancer.

9 March 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
APAwais Paracha
Awais Paracha
DTDerek Tran
Derek Tran
MNMargot Noyelle
Margot Noyelle
JKJonathan Kapilian
Jonathan Kapilian
ZSZohair Siddiqui
Zohair Siddiqui
XZXin-Hua Zhu
Xin-Hua Zhu
Background: Prostate cancer (PC) is the most common cancer in men in the United States with a 5-year relative survival rate for people with distant metastases of 36%. We conducted a single institution, retrospective cohort study of patients with metastatic PC to investigate whether certain gene mutations can be used as predictive biomarkers. Methods: 200 patients with metastatic hormone sensitive (mHSPC) and castration resistant (mCRPC) prostate cancer who had a FoundationOne report and were treated from June 2007 to October 2024 were included in the study. Disease progression was evaluated according to RECIST criteria, PCWG3 criteria, and PSA values. Assessed gene mutations included SPOP, p53, Rb, PTEN , and HRR genes. Overall survival (OS) and progression-free survival (PFS) were calculated for mHSPC and mCRPC. Results: Among 200 patients, there were 182 patients with mHSPC and 174 patients with mCRPC. Average age at diagnosis of metastatic disease was 71.5, ECOG was 0.76, and median PSA was 75.6 ng/mL. 152 patients had high-volume disease. 102 patients passed away. Patients with a p53 mutation (n=99) had lower OS in mHSPC (50.7 months vs 86.2 months, p<0.01). Patients with a PTEN mutation (n=50) had a lower OS in mHSPC (50.6 months vs 65.8 months, p=0.03) and mCRPC (29.5 months vs 46.0 months, p=0.04). Patients with HRR mutations (n=43) had lower OS in mHSPC (41.4 months vs 64.6 months, p<0.01) and mCRPC (18.4 months vs 42.8 months, p=0.04). p53 and PTEN mutations were associated with shorter PFS in mCRPC (13.8 months vs 23.2 months, p=0.03; 12.2 months vs 22.6 months, p<0.01, respectively). Mutations in SPOP (n=13 mHSPC, n=9 mCRPC) and RB1 (n=12 mHSPC, n=10 mCRPC) were not associated with statistically significant differences in OS and PFS. Conclusions: PTEN , and HRR mutations were associated with shorter OS in both mHSPC and mCRPC. p53 mutations are associated with shorter OS only in mHSPC. p53 and PTEN mutations were associated with shorter PFS only in mCRPC.